NSAID labeling cost projection grows
This article was originally published in The Tan Sheet
Executive Summary
FDA raises its estimate of industry costs in a final rule requiring organ-specific label warnings for OTC products containing acetaminophen or nonsteroidal anti-inflammatory drugs by April 29, 2010. The revised rulemaking bumps up first-year, one-time, industry-wide re-labeling costs to $62.7 million from $32.6 million, according to a June 30 Federal Register notice. FDA says its April 29 estimate of the products affected by the final rule underestimated the proportion of affected NSAID products, which will need expanded inner blister pack containers and outer cartons to accommodate the additional warnings. Packaging for OTC acetaminophen will not need to be made larger, FDA says. FDA still projects the total number of SKUs affected at 18,000, while industry consultant Eastern Research Group says it could be as high as 25,000 (1"The Tan Sheet" May 4, 2009)
You may also be interested in...
FDA Expands Acetaminophen, NSAID Labeling Beyond Tentative Final Rule
FDA's final rule for OTC products containing acetaminophen or nonsteroidal anti-inflammatory drugs requires warnings and revisions that go beyond changes the agency proposed in a 2006 tentative final rule
COVID-19 Redefining Clinical Trial Transparency Expectations & Challenges
A senior Pfizer executive talks about the high regulatory expectations for public disclosure of clinical trial data for Comirnaty, the COVID-19 vaccine it developed in partnership with BioNTech. There were also concerns about re-identification of trial participants as many subjects took to social media to share their experiences with the Comirnaty study.
Top Senator ‘Disappointed’ With Missing MDUFA Package
Sen. Patty Murray said she doesn’t want more uncertainty about user fees during the COVID-19 pandemic and will move to get all the user fees renewed before they expire in September.